@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_head { this: np:hasAssertion dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_assertion; np:hasProvenance dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_provenance; np:hasPublicationInfo dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_publicationInfo; a np:Nanopublication . dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_assertion a np:Assertion . dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_provenance a np:Provenance . dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_publicationInfo a np:PublicationInfo . } dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_assertion { miriam-gene:3791 a ncit:C16612 . lld:C0005684 a ncit:C7057 . dgn-gda:DGN48778ca7e1d1e7a97d7e366b8722bac8 sio:SIO_000628 miriam-gene:3791, lld:C0005684; a sio:SIO_001121 . } dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_provenance { dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_assertion dcterms:description "[Among these genes, it appears that: PPARG promotes the PPAR signaling pathway via the upregulation of lipoprotein lipase (LPL) expression, but suppresses the cell cycle pathway via downregulation of growth arrest and DNA-damage-inducible, γ (GADD45G) expression; ETV4 stimulates matrix metallopeptidase 9 (MMP9) expression to induce the bladder cancer pathway; FLI upregulates transforming growth factor, β receptor II (TGFBR2) expression to activate TGF-β signaling and upregulates cyclin D3 (CCND3) expression to promote the cell cycle pathway; NFKB1 upregulates interleukin 1, β (IL-1B) expression and initiates the prostate cancer pathway; CEBPB upregulates IL-6 expression and promotes pathways in cancer; and TAL1 promotes kinase insert domain receptor (KDR) expression to promote the TGF-β signaling pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:22895549; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP1005391.RAGeZXgYcL-gl0c9fMphGL8QzzHAA99C_W9qrl51A6yvY130_publicationInfo { this: dcterms:created "2016-05-13T12:49:21+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }